Globe Life’s (GL) Outperform Rating Reaffirmed at Keefe, Bruyette & Woods

Keefe, Bruyette & Woods reaffirmed their outperform rating on shares of Globe Life (NYSE:GL) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $168.00 target price on the stock.

A number of other equities analysts also recently commented on GL. Weiss Ratings upgraded shares of Globe Life from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. raised their price target on Globe Life from $180.00 to $181.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Evercore set a $157.00 price target on Globe Life in a report on Wednesday, February 18th. Morgan Stanley reaffirmed an “overweight” rating and set a $176.00 price objective on shares of Globe Life in a research report on Monday, December 15th. Finally, Wells Fargo & Company increased their price objective on Globe Life from $170.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $172.00.

Globe Life Stock Up 0.9%

Shares of NYSE:GL opened at $138.74 on Thursday. Globe Life has a fifty-two week low of $109.38 and a fifty-two week high of $152.71. The firm’s 50 day moving average price is $141.52 and its 200 day moving average price is $138.89. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.39. The stock has a market cap of $10.88 billion, a price-to-earnings ratio of 9.85 and a beta of 0.46.

Globe Life (NYSE:GL) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $3.39 EPS for the quarter, missing the consensus estimate of $3.44 by ($0.05). Globe Life had a return on equity of 21.30% and a net margin of 19.37%.The firm had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter last year, the firm earned $3.14 EPS. The company’s revenue was up 3.6% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 14.950-15.650 EPS. As a group, equities research analysts predict that Globe Life will post 13.87 earnings per share for the current fiscal year.

Globe Life Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Friday, April 3rd will be issued a $0.33 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This is an increase from Globe Life’s previous quarterly dividend of $0.27. This represents a $1.32 annualized dividend and a dividend yield of 1.0%. Globe Life’s dividend payout ratio is currently 7.67%.

Insider Buying and Selling at Globe Life

In other news, CMO Jennifer Allison Haworth sold 10,000 shares of Globe Life stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $143.14, for a total value of $1,431,400.00. Following the transaction, the chief marketing officer directly owned 17,479 shares of the company’s stock, valued at $2,501,944.06. The trade was a 36.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James Matthew Darden sold 18,318 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $145.10, for a total transaction of $2,657,941.80. Following the completion of the sale, the chief executive officer owned 51,093 shares of the company’s stock, valued at approximately $7,413,594.30. This trade represents a 26.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 82,807 shares of company stock valued at $12,041,286. 1.51% of the stock is owned by company insiders.

Institutional Investors Weigh In On Globe Life

Institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Globe Life by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,391 shares of the company’s stock valued at $1,237,000 after acquiring an additional 607 shares during the period. NewEdge Advisors LLC lifted its position in Globe Life by 368.1% during the 1st quarter. NewEdge Advisors LLC now owns 6,806 shares of the company’s stock worth $897,000 after acquiring an additional 5,352 shares during the period. Goldman Sachs Group Inc. lifted its position in Globe Life by 11.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 563,021 shares of the company’s stock worth $74,161,000 after acquiring an additional 58,163 shares during the period. Empowered Funds LLC purchased a new position in shares of Globe Life in the 1st quarter valued at approximately $428,000. Finally, Focus Partners Wealth grew its stake in shares of Globe Life by 8.3% in the 1st quarter. Focus Partners Wealth now owns 8,559 shares of the company’s stock valued at $1,127,000 after purchasing an additional 656 shares during the last quarter. 81.61% of the stock is owned by hedge funds and other institutional investors.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.